Sugi Predict

Sugi Predict / Compounds / Metomidate

Metomidate

Metomidate

SCHEMBL491910

COC(=O)c1cncn1C(C)c1ccccc1

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.97
▸ GABRA1 P14867 7/20 0.74
▸ GABRB2 P47870 6/20 0.74
▸ CYP11B1 P15538 3/20 0.74
▸ CYP11B2 P19099 3/20 0.74
▸ CYP1A2 P05177 2/20 0.74
▸ CYP3A4 P08684 2/20 0.74
▸ LMNA P02545 1/20 0.74
▸ CYP2C9 P11712 1/20 0.74
▸ CYP2C19 P33261 1/20 0.74
▸ ABCB11 O95342 1/20 0.74
▸ GABRA2 P47869 1/20 0.74
▸ ALDH1A1 P00352 1/20 0.74
▸ TDP1 Q9NUW8 1/20 0.74
▸ GPBAR1 Q8TDU6 4/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ MAPT P10636 1/20 0.44
▸ MEN1 O00255 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Metomidate SCHEMBL4377172 1.00 MAPK1 (0.97) MAPK1GABRA1GABRB2CYP11B1CYP11B2
Metomidate SCHEMBL1845324 0.99 MAPK1 (1.00) MAPK1GABRA1GABRB2CYP11B1CYP11B2
Metomidate SCHEMBL11733503 0.95 MAPK1 (0.88) MAPK1GABRA1GABRB2CYP11B1CYP11B2
SCHEMBL15125287 0.88 MAPK1 (0.76) MAPK1GABRA1GABRB2CYP11B1CYP11B2
SCHEMBL15125277 0.88 MAPK1 (0.76) MAPK1GABRA1GABRB2CYP11B1CYP11B2
SCHEMBL19062800 0.88 MAPK1 (0.76) MAPK1GABRA1GABRB2CYP11B1CYP11B2
SCHEMBL31406537 0.87 MAPK1 (0.76) MAPK1GABRA1GABRB2CYP11B1CYP11B2
SCHEMBL22004285 0.87 MAPK1 (0.76) MAPK1GABRA1GABRB2CYP11B1CYP11B2
SCHEMBL22259496 0.87 MAPK1 (0.75) MAPK1GABRA1GABRB2CYP11B1CYP11B2
SCHEMBL19063063 0.87 MAPK1 (0.75) MAPK1GABRA1GABRB2CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 680 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250185632-A1 CONTINUOUS IN-SITU THERAPEUTIC TREATMENT SYSTEM FOR FISH IN FRESHWATER, FROM SEAWATER Salmoclinic Spa (CL) 2025-06-12 — — US claimed
EP-4460178-A1 METHOD TO DETACH ECTOPARASITES FROM FISH Intervet International B.V. (NL) 2024-11-13 — — EP claimed
WO-2023131615-A1 METHOD TO DETACH ECTOPARASITES FROM FISH INTERVET INTERNATIONAL B.V. (NL) 2023-07-13 — — WO claimed
US-20220273600-A1 LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2022-09-01 — — US claimed
WO-2022087757-A1 CONTINUOUS IN-SITU THERAPEUTIC TREATMENT SYSTEM FOR FRESHWATER FISH USING SEAWATER KOSSMANN PERL HANS JORG (CL) 2022-05-05 — — WO claimed
EP-3651759-A1 LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF Syneurx International (Taiwan) Corp. (TW) 2020-05-20 — — EP claimed
US-10226442-B2 Lithium salts of N-substituted glycine compounds and uses thereof SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2019-03-12 — — US claimed
WO-2019014207-A1 LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2019-01-17 — — WO claimed
US-20190008813-A1 LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2019-01-10 — — US claimed
CN-104569264-B A kind of assay method of Etomidate related substance LI HONG (CN) 2016-05-18 — — CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
EP-1911481-A2 Methods and systems of delivering medication via inhalation Next Safety, Inc. (US) 2008-04-16 — — EP claimed
US-20080078382-A1 Methods and Systems of Delivering Medication Via Inhalation HUNTER, CHARLES ERIC 2008-04-03 — — US claimed
WO-2008036798-A2 METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION NEXT SAFETY, INC. (US) 2008-03-27 — — WO claimed
WO-2008036801-A2 METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION NEXT SAFETY, INC. (US) 2008-03-27 — — WO claimed
EP-1902742-A1 Methods and systems of delivering medication via inhalation Next Safety, Inc. (US) 2008-03-26 — — EP claimed
US-20080066739-A1 METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION HUNTER, CHARLES ERIC 2008-03-20 — — US claimed
US-20080066741-A1 METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION HUNTER, CHARLES ERIC 2008-03-20 — — US claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220273600-A1 LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF SLC1A2, SLC6A5, SLC1A1 MAPK1 3567/4885GABRA1 900/4885GABRB2 1194/4885
US-10226442-B2 Lithium salts of N-substituted glycine compounds and uses thereof SLC1A2, SLC6A5, SLC1A1 MAPK1 3567/4885GABRA1 900/4885GABRB2 1194/4885
US-20190008813-A1 LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF SLC1A2, SLC6A5, SLC1A1 MAPK1 3567/4885GABRA1 900/4885GABRB2 1194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.